1092394-15-4

Basic information

• Product Name: 6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine
• Synonyms: 6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine;6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine
• CAS NO: 1092394-15-4
• Molecular Formula: C7H8N4O
• Molecular Weight: 164.16462
• Mol File: 1092394-15-4.mol

Chemical Properties

• Appearance: /
• Density: 1.48
• CAS DataBase Reference: 6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine(1092394-15-4)
• EPA Substance Registry System: 6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine(1092394-15-4)

Safety Data

• Hazardous Substances Data: 1092394-15-4(Hazardous Substances Data)

Usage

Uses

Since the specific applications or uses of 6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine in various industries or scientific research have not been widely documented, it is not possible to provide a detailed list of its uses. However, given its chemical structure and belonging to the class of methoxytriazolopyridines, it may potentially be used in the following areas:
1. Used in Pharmaceutical Industry:
6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine could be used as a building block or intermediate in the synthesis of pharmaceutical compounds, given its unique chemical structure and potential reactivity.
2. Used in Chemical Research:
6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine may be utilized in chemical research to study its reactivity, stability, and potential interactions with other molecules, which could lead to the development of new chemical processes or materials.
3. Used in Material Science:
The unique structure of 6-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine may offer specific properties that could be exploited in the development of new materials with tailored characteristics for various applications.

Upstream product

• 1092394-14-3 ethyl {[(5-methoxypyridin-2-yl)amino]carbonothioyl}carbamate 
• 10167-97-2 2-amino-5-methoxypyridine 

Downstream Products

• 1195781-62-4 N-[6-(2-fluoro-4-nitrophenoxy)[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide 
• 1195781-63-5 N-[6-(4-amino-2-fluorophenoxy)[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide 
• 1092391-65-5 N-[3-({2-[(cyclopropylcarbonyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}oxy)-5-fluorophenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide 
• 1092394-69-8 N-[6-(3-fluoro-5-nitrophenoxy)[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide 
• 1092394-16-5 2-amino[1,2,4]triazolo[1,5-a]pyridin-6-ol hydrobromide 

Relevant articles and documents

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF

The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specificatio

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS

A compound represented by the formula (I): wherein Z1,Z2,Z3 and Z4 are the following combination, (Z1,Z2,Z3,Z4)=(CR4,N,CR5,C), (N,N,CR5,C), (N,C,CR5,N), (S,C,CR5,C) or (S,C,N,C); R1 and R2 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R 3 is an amino optionally having substituent(s); R4 and R 5 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R3 and R4 optionally form a ring optionally having substituent(s); and a group represented by the formula (A) is a cyclic group optionally having substituent(s), or a salt thereof